☰

Alessio Giubellino, MD, PhD - Publications

Affiliations: 
2003-2010 Urologic Oncology Branch National Cancer Institue-NIH 
 2015- Laboratory Medicine and Pathology University of Minnesota Medical School, Minneapolis, MN, United States 
Tree Info Similar researchers PubMed Report error

40 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Song KY, Desar S, Pengo T, Shanley R, Giubellino A. Correlation of MET and PD-L1 Expression in Malignant Melanoma. Cancers. 12. PMID 32659961 DOI: 10.3390/Cancers12071847  0.347
2020 Kwon D, Ronen S, Giubellino A, Keiser E, Aung PP, Nagarajan P, Tetzlaff MT, Ivan D, Curry JL, Prieto VG, Torres-Cabala CA. Cutaneous Adnexal Carcinosarcoma: Immunohistochemical and Molecular Evidence of Epithelial Mesenchymal Transition. Journal of Cutaneous Pathology. PMID 32564423 DOI: 10.1111/Cup.13782  0.355
2020 Toyama A, Bell WR, Giubellino A, Li F. Lipoblast-Like Morphology in a Uveal Melanoma with Delayed Metastasis to the Liver. Ocular Oncology and Pathology. 6: 87-92. PMID 32258015 DOI: 10.1159/000501619  0.324
2019 Zhou Y, Song KY, Giubellino A. The role of MET in melanoma and melanocytic lesions. The American Journal of Pathology. PMID 31476283 DOI: 10.1016/J.Ajpath.2019.08.002  0.384
2019 Toyama A, Siegel L, Nelson AC, Najmuddin M, Bu L, LaRue R, Henzler C, Caicedo-Granados E, Giubellino A, Li F. Analyses of molecular and histopathologic features and expression of PRAME by immunohistochemistry in mucosal melanomas. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 31375769 DOI: 10.1038/S41379-019-0335-4  0.312
2015 Giubellino A, Lara K, Martucci V, Huynh T, Agarwal P, Pacak K, Merino MJ. Urinary Bladder Paragangliomas: How Immunohistochemistry Can Assist to Identify Patients With SDHB Germline and Somatic Mutations. The American Journal of Surgical Pathology. 39: 1488-92. PMID 26457353 DOI: 10.1097/Pas.0000000000000534  0.315
2015 Schovanek J, Bullova P, Tayem Y, Giubellino A, Wesley R, Lendvai N, Nölting S, Kopacek J, Frysak Z, Pommier Y, Kummar S, Pacak K. Inhibitory Effect of the Noncamptothecin Topoisomerase I Inhibitor LMP-400 on Female Mice Models and Human Pheochromocytoma Cells. Endocrinology. 156: 4094-104. PMID 26267380 DOI: 10.1210/En.2015-1476  0.389
2015 Kaye DR, Pinto PA, Cecchi F, Reilly J, Semerjian A, Giubellino A, Gupta G, Choyke PL, Linehan WM, Bottaro DP. MP6-17 PREDICTIVE VALUE OF PLASMA SOLUBLE MET PROTEIN CONCENTRATION IN PATIENTS WITH PROSTATE CANCER Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.264  0.727
2014 McNeil BK, Sorbellini M, Grubb RL, Apolo A, Cecchi F, Athauda G, Cohen B, Giubellino A, Simpson H, Agarwal PK, Coleman J, Getzenberg RH, Netto GJ, Shih J, Linehan WM, et al. Preliminary evaluation of urinary soluble Met as a biomarker for urothelial carcinoma of the bladder. Journal of Translational Medicine. 12: 199. PMID 25335552 DOI: 10.1186/1479-5876-12-199  0.758
2014 Nölting S, Giubellino A, Tayem Y, Young K, Lauseker M, Bullova P, Schovanek J, Anver M, Fliedner S, Korbonits M, Göke B, Vlotides G, Grossman A, Pacak K. Combination of 13-Cis retinoic acid and lovastatin: marked antitumor potential in vivo in a pheochromocytoma allograft model in female athymic nude mice. Endocrinology. 155: 2377-90. PMID 24762141 DOI: 10.1210/En.2014-1027  0.317
2014 Giubellino A, Shankavaram U, Bullova P, Schovanek J, Zhang Y, Shen M, Patel N, Elkahloun A, Lee MJ, Trepel J, Ferrer M, Pacak K. High-throughput screening for the identification of new therapeutic options for metastatic pheochromocytoma and paraganglioma. Plos One. 9: e90458. PMID 24699253 DOI: 10.1371/Journal.Pone.0090458  0.318
2014 Powers JF, Korgaonkar PG, Fliedner S, Giubellino A, Pacak K, Sahagian GG, Tischler AS. Cytocidal activities of topoisomerase 1 inhibitors and 5-azacytidine against pheochromocytoma/paraganglioma cells in primary human tumor cultures and mouse cell lines. Plos One. 9: e87807. PMID 24516563 DOI: 10.1371/Journal.Pone.0087807  0.37
2013 Ghayee HK, Giubellino A, Click A, Kapur P, Christie A, Xie XJ, Martucci V, Shay JW, Souza RF, Pacak K. Phospho-mTOR is not upregulated in metastatic SDHB paragangliomas. European Journal of Clinical Investigation. 43: 970-7. PMID 23889685 DOI: 10.1111/Eci.12127  0.325
2013 Giubellino A, Sourbier C, Lee MJ, Scroggins B, Bullova P, Landau M, Ying W, Neckers L, Trepel JB, Pacak K. Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma. Plos One. 8: e56083. PMID 23457505 DOI: 10.1371/Journal.Pone.0056083  0.345
2013 Matro J, Giubellino A, Pacak K. Current and future therapeutic approaches for metastatic pheochromocytoma and paraganglioma: focus on SDHB tumors. Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme. 45: 147-53. PMID 23322515 DOI: 10.1055/S-0032-1331211  0.317
2013 Giubellino A, Bullova P, Nölting S, Turkova H, Powers JF, Liu Q, Guichard S, Tischler AS, Grossman AB, Pacak K. Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice. Endocrinology. 154: 646-55. PMID 23307788 DOI: 10.1210/En.2012-1854  0.385
2012 Nölting S, Garcia E, Alusi G, Giubellino A, Pacak K, Korbonits M, Grossman AB. Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines. Journal of Molecular Endocrinology. 49: 79-96. PMID 22715163 DOI: 10.1530/Jme-12-0028  0.36
2012 Pacak K, Sirova M, Giubellino A, Lencesova L, Csaderova L, Laukova M, Hudecova S, Krizanova O. NF-κB inhibition significantly upregulates the norepinephrine transporter system, causes apoptosis in pheochromocytoma cell lines and prevents metastasis in an animal model. International Journal of Cancer. 131: 2445-55. PMID 22407736 DOI: 10.1002/Ijc.27524  0.334
2012 Giubellino A, Woldemichael GM, Sourbier C, Lizak MJ, Powers JF, Tischler AS, Pacak K. Characterization of two mouse models of metastatic pheochromocytoma using bioluminescence imaging. Cancer Letters. 316: 46-52. PMID 22154086 DOI: 10.1016/J.Canlet.2011.10.019  0.328
2012 Sorbellini M, McNeil B, Giubellino A, Dharmawardana G, Simpson H, Coleman J, Getzenberg R, Netto G, Pinto P, Linehan M, Bottaro D. 1283 URINARY MET LEVEL AS A NOVEL BIOMARKER FOR UROTHELIAL CARCINOMA OF THE BLADDER Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.1615  0.552
2011 Sorbellini M, Giubellino A, Srivastava G, Sourbier C, Pinto PA, Linehan W, Bottaro DP. Effect of the orally available MET inhibitor PF-2341066 on tumor burden and metastasis in an orthotopic xenograft model of bladder cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 263. PMID 27968590 DOI: 10.1200/Jco.2011.29.7_Suppl.263  0.614
2011 Sorbellini M, Giubellino A, Srivastava G, Sourbier C, Jagoda E, Williams M, Choyke PL, Pinto PA, Linehan W, Bottaro DP. Use of a MET-specific photoprobe to identify bladder tumors in an orthotopic xenograft model of bladder cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 260. PMID 27968576 DOI: 10.1200/Jco.2011.29.7_Suppl.260  0.613
2011 Sorbellini M, McNeil B, Cohen B, Athauda G, Giubellino A, Coleman J, Netto GJ, Getzenberg RH, Linehan W, Bottaro DP. Urinary Met level as a novel biomarker for urothelial carcinoma of the bladder. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 257. PMID 27968502 DOI: 10.1200/Jco.2011.29.7_Suppl.257  0.747
2011 Liu F, Giubellino A, Simister PC, Qian W, Giano MC, Feller SM, Bottaro DP, Burke TR. Application of ring-closing metathesis to Grb2 SH3 domain-binding peptides. Biopolymers. 96: 780-8. PMID 21830199 DOI: 10.1002/Bip.21692  0.528
2010 Sourbier C, Valera-Romero V, Giubellino A, Yang Y, Sudarshan S, Neckers L, Linehan WM. Increasing reactive oxygen species as a therapeutic approach to treat hereditary leiomyomatosis and renal cell carcinoma. Cell Cycle (Georgetown, Tex.). 9: 4183-9. PMID 20953139 DOI: 10.4161/Cc.9.20.13458  0.357
2010 Felici A, Giubellino A, Bottaro DP. Gab1 mediates hepatocyte growth factor-stimulated mitogenicity and morphogenesis in multipotent myeloid cells. Journal of Cellular Biochemistry. 111: 310-21. PMID 20506405 DOI: 10.1002/Jcb.22695  0.577
2010 Sorbellini M, McNeil B, Simpson H, Giubellino A, Hsieh T, Getzenberg RH, Schoenberg M, Gagani C, Bottaro DP. Correlation of Met expression in TCC of the bladder with stage and grade. Journal of Clinical Oncology. 28: e15110-e15110. DOI: 10.1200/Jco.2010.28.15_Suppl.E15110  0.568
2010 Niswander LM, Guenther LM, Cecchi F, Giubellino A, Bottaro DP, Christensen JG, Khanna C, Helman LJ, Kim SY. Abstract 3401: Genetic down-regulation of MET alters the metastatic phenotype of osteosarcoma cells Cancer Research. 70: 3401-3401. DOI: 10.1158/1538-7445.Am10-3401  0.711
2009 Giubellino A, Linehan WM, Bottaro DP. Targeting the Met signaling pathway in renal cancer Expert Review of Anticancer Therapy. 9: 785-793. PMID 19496715 DOI: 10.1586/Era.09.43  0.604
2009 Choi WJ, Kim SE, Stephen AG, Weidlich I, Giubellino A, Liu F, Worthy KM, Bindu L, Fivash MJ, Nicklaus MC, Bottaro DP, Fisher RJ, Burke TR. Identification of Shc Src homology 2 domain-binding peptoid-peptide hybrids. Journal of Medicinal Chemistry. 52: 1612-8. PMID 19226165 DOI: 10.1021/Jm800789H  0.532
2009 Peach ML, Tan N, Choyke SJ, Giubellino A, Athauda G, Burke TR, Nicklaus MC, Bottaro DP. Directed discovery of agents targeting the Met tyrosine kinase domain by virtual screening. Journal of Medicinal Chemistry. 52: 943-51. PMID 19199650 DOI: 10.1021/Jm800791F  0.749
2009 Le Pape E, Passeron T, Giubellino A, Valencia JC, Wolber R, Hearing VJ. Microarray analysis sheds light on the dedifferentiating role of agouti signal protein in murine melanocytes via the Mc1r. Proceedings of the National Academy of Sciences of the United States of America. 106: 1802-7. PMID 19174519 DOI: 10.1073/Pnas.0806753106  0.399
2009 Giubellino A, Liu F, Burke T, Bottaro DP. Abstract A163: Development of Grb2 SH3 domain antagonists Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-A163  0.625
2008 Giubellino A, Shi ZD, Jenkins LM, Worthy KM, Bindu LK, Athauda G, Peruzzi B, Fisher RJ, Appella E, Burke TR, Bottaro DP. Selectivity and mechanism of action of a growth factor receptor-bound protein 2 SRC homology 2 domain binding antagonist. Journal of Medicinal Chemistry. 51: 7459-68. PMID 18989951 DOI: 10.1021/Jm800523U  0.736
2008 Giubellino A, Burke TR, Bottaro DP. Grb2 signaling in cell motility and cancer. Expert Opinion On Therapeutic Targets. 12: 1021-33. PMID 18620523 DOI: 10.1517/14728222.12.8.1021  0.602
2007 Giubellino A, Gao Y, Lee S, Lee MJ, Vasselli JR, Medepalli S, Trepel JB, Burke TR, Bottaro DP. Inhibition of tumor metastasis by a growth factor receptor bound protein 2 Src homology 2 domain-binding antagonist. Cancer Research. 67: 6012-6. PMID 17616655 DOI: 10.1158/0008-5472.Can-07-0022  0.655
2007 Liu F, Worthy KM, Bindu L, Giubellino A, Bottaro DP, Fisher RJ, Burke TR. Utilization of achiral alkenyl amines for the preparation of high affinity Grb2 SH2 domain-binding macrocycles by ring-closing metathesis. Organic & Biomolecular Chemistry. 5: 367-72. PMID 17205182 DOI: 10.1039/B611887A  0.544
2006 Athauda G, Giubellino A, Coleman JA, Horak C, Steeg PS, Lee MJ, Trepel J, Wimberly J, Sun J, Coxon A, Burgess TL, Bottaro DP. c-Met ectodomain shedding rate correlates with malignant potential. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4154-62. PMID 16857786 DOI: 10.1158/1078-0432.Ccr-06-0250  0.761
2006 Dharmawardana PG, Peruzzi B, Giubellino A, Burke TR, Bottaro DP. Molecular targeting of growth factor receptor-bound 2 (Grb2) as an anti-cancer strategy. Anti-Cancer Drugs. 17: 13-20. PMID 16317285 DOI: 10.1097/01.Cad.0000185180.72604.Ac  0.765
2004 Dharmawardana PG, Giubellino A, Bottaro DP. Hereditary papillary renal carcinoma type I. Current Molecular Medicine. 4: 855-68. PMID 15579033 DOI: 10.2174/1566524043359674  0.601
Show low-probability matches.